Galecto, Inc. (GLTO)
NASDAQ: GLTO · Real-Time Price · USD
29.66
-0.34 (-1.13%)
Feb 23, 2026, 4:00 PM EST - Market closed
Company Description
Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases.
The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications.
Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Galecto, Inc.
| Country | Denmark |
| Founded | 2011 |
| IPO Date | Oct 29, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Sherwin Sattarzadeh |
Contact Details
Address: Ole Maaloes Vej 3, Copenhagen N Copenhagen, 2200 Denmark | |
| Phone | 45 70 70 52 10 |
| Website | galecto.com |
Stock Details
| Ticker Symbol | GLTO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 1800315 |
| CUSIP Number | 36322Q107 |
| ISIN Number | US36322Q2066 |
| Employer ID | 37-1957007 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ulf J. Nilsson Ph.D. | Co-Founder |
| Dr. Hakon Leffler M.D., Ph.D. | Co-Founder |
| Prof. Tariq Sethi B.Sc., FRCP, M.A., M.D., Ph.D. | Co-Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 17, 2026 | SCHEDULE 13G | Filing |
| Feb 17, 2026 | SCHEDULE 13G | Filing |
| Feb 11, 2026 | SCHEDULE 13D/A | Filing |
| Feb 11, 2026 | 8-K | Current Report |
| Feb 11, 2026 | 424B5 | Filing |
| Feb 10, 2026 | 424B5 | Filing |
| Feb 10, 2026 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Feb 10, 2026 | 8-K | Current Report |
| Jan 12, 2026 | SCHEDULE 13G | Filing |
| Jan 12, 2026 | SCHEDULE 13G | Filing |